Literature DB >> 12638937

Emergency management of inherited metabolic diseases.

V Prietsch1, M Lindner, J Zschocke, W L Nyhan, G F Hoffmann.   

Abstract

Inherited metabolic diseases with acute severe manifestations can be divided into five categories: (1) disorders of the intoxication type, (2) disorders with reduced fasting tolerance, (3) disorders with disturbed energy metabolism, (4) disorders of neurotransmission and (5) disorders in which no specific emergency treatment is available. Diagnostic emergency laboratory evaluation should cover all differential diagnoses that are therapeutically relevant and should always include ammonia, glucose, lactate and acid-base status as well as testing the urine for ketones. These are indispensable for planning and conducting the first steps of metabolic emergency treatment and should be available within 30 min. According to the clinical situation and biochemical derangement, special metabolic investigations must be initiated in parallel. These include acylcarnitine profiling with tandem mass spectrometry (in plasma or dried blood spots) and analysis of amino acids in plasma and of organic acids in urine. The results of all laboratory investigations relevant to the diagnosis of metabolic disorders for which specific emergency therapy exists should be available within 24 h. There is general agreement with regard to some therapeutic strategies that are clearly explained by pathophysiology: in disorders with endogenous intoxication, anabolism must be promoted and specific detoxification measures initiated. In disorders with reduced fasting tolerance, administration of glucose at the rate of hepatic glucose production forms the basis of treatment. Correction of acidosis is a major goal in disorders with disturbed mitochondrial energy metabolism, while glucose supply may have to be limited. Many current therapeutic strategies are based on case reports and personal experiences at different metabolic centres. The aim of devising the 'best' management is often hampered by the lack of objective evidence of efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12638937     DOI: 10.1023/a:1022040422590

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  35 in total

1.  Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in patients with maple syrup urine disease.

Authors:  G T Berry; R Heidenreich; P Kaplan; F Levine; A Mazur; M J Palmieri; M Yudkoff; S Segal
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

Review 2.  Assessment of energy expenditure in metabolic disorders.

Authors:  O A Bodamer; G F Hoffmann; G H Visser; A Janecke; O Linderkamp; J V Leonard; L Fasoli; D Rating
Journal:  Eur J Pediatr       Date:  1997-08       Impact factor: 3.183

3.  Resting energy expenditure in disorders of propionate metabolism.

Authors:  F Feillet; O A Bodamer; M A Dixon; S Sequeira; J V Leonard
Journal:  J Pediatr       Date:  2000-05       Impact factor: 4.406

4.  Secondary carnitine deficiency in hyperammonemic attacks of ornithine transcarbamylase deficiency.

Authors:  Y Ohtani; K Ohyanagi; S Yamamoto; I Matsuda
Journal:  J Pediatr       Date:  1988-03       Impact factor: 4.406

5.  Postoperative metabolic decompensation in maple syrup urine disease is completely prevented by insulin.

Authors:  B Biggemann; R Zass; U Wendel
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism.

Authors:  G N Thompson; W W Butt; F A Shann; D M Kirby; R D Henning; D W Howells; A Osborne
Journal:  J Pediatr       Date:  1991-06       Impact factor: 4.406

7.  Pharmacologic amino acid acylation in the acute hyperammonemia of propionic acidemia.

Authors:  S Petrowski; W L Nyhan; V Reznik; L Sweetman; S Kulovich; J Wolff; G Jones
Journal:  J Neurogenet       Date:  1987-04       Impact factor: 1.250

Review 8.  Alternative pathway therapy for urea cycle disorders.

Authors:  F Feillet; J V Leonard
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

9.  Inhibition of pyruvate carboxylase by sequestration of coenzyme A with sodium benzoate.

Authors:  A D Griffith; D M Cyr; S G Egan; G C Tremblay
Journal:  Arch Biochem Biophys       Date:  1989-02-15       Impact factor: 4.013

10.  A case of carbamylphosphate synthetase-I deficiency associated with secondary carnitine deficiency--L-carnitine treatment of CPS-I deficiency.

Authors:  T Mori; A Tsuchiyama; K Nagai; M Nagao; K Oyanagi; S Tsugawa
Journal:  Eur J Pediatr       Date:  1990-01       Impact factor: 3.183

View more
  21 in total

Review 1.  Acute management of propionic acidemia.

Authors:  Kimberly A Chapman; Andrea Gropman; Erin MacLeod; Kathy Stagni; Marshall L Summar; Keiko Ueda; Nicholas Ah Mew; Jill Franks; Eddie Island; Dietrich Matern; Loren Pena; Brittany Smith; V Reid Sutton; Tiina Urv; Charles Venditti; Anupam Chakrapani
Journal:  Mol Genet Metab       Date:  2011-09-24       Impact factor: 4.797

Review 2.  Emergency treatment in glutaryl-CoA dehydrogenase deficiency.

Authors:  S Kölker; C R Greenberg; M Lindner; E Müller; E R Naughten; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I).

Authors:  S Kölker; E Christensen; J V Leonard; C R Greenberg; A B Burlina; A P Burlina; M Dixon; M Duran; S I Goodman; D M Koeller; E Müller; E R Naughten; E Neumaier-Probst; J G Okun; M Kyllerman; R A Surtees; B Wilcken; G F Hoffmann; P Burgard
Journal:  J Inherit Metab Dis       Date:  2007-01-03       Impact factor: 4.982

Review 4.  Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.

Authors:  Katharina Danhauser; Jan A M Smeitink; Peter Freisinger; Wolfgang Sperl; Hemmen Sabir; Berit Hadzik; Ertan Mayatepek; Eva Morava; Felix Distelmaier
Journal:  J Inherit Metab Dis       Date:  2015-02-17       Impact factor: 4.982

Review 5.  Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision.

Authors:  Nikolas Boy; Chris Mühlhausen; Esther M Maier; Jana Heringer; Birgit Assmann; Peter Burgard; Marjorie Dixon; Sandra Fleissner; Cheryl R Greenberg; Inga Harting; Georg F Hoffmann; Daniela Karall; David M Koeller; Michael B Krawinkel; Jürgen G Okun; Thomas Opladen; Roland Posset; Katja Sahm; Johannes Zschocke; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-11-16       Impact factor: 4.982

6.  Eight novel MUT loss-of-function missense mutations in Chinese patients with isolated methylmalonic academia.

Authors:  Lian-Shu Han; Zhuo Huang; Feng Han; Yu Wang; Zhu-Wen Gong; Xue-Fan Gu
Journal:  World J Pediatr       Date:  2017-01-19       Impact factor: 2.764

Review 7.  Renal transplant in methylmalonic acidemia: could it be the best option? Report on a case at 10 years and review of the literature.

Authors:  Riccardo Lubrano; Marco Elli; Massimo Rossi; Elisabetta Travasso; Claudia Raggi; Paola Barsotti; Claudia Carducci; Pasquale Berloco
Journal:  Pediatr Nephrol       Date:  2007-03-31       Impact factor: 3.714

Review 8.  Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases.

Authors:  Kei Murayama; Masaru Shimura; Zhimei Liu; Yasushi Okazaki; Akira Ohtake
Journal:  J Hum Genet       Date:  2018-11-21       Impact factor: 3.172

9.  A modern approach to the treatment of mitochondrial disease.

Authors:  Sumit Parikh; Russell Saneto; Marni J Falk; Irina Anselm; Bruce H Cohen; Richard Haas; The Mitochondrial Medicine Society
Journal:  Curr Treat Options Neurol       Date:  2009-11       Impact factor: 3.598

10.  Acute hemodialysis for hyperammonemia in small neonates.

Authors:  Deepak K Rajpoot; John J Gargus
Journal:  Pediatr Nephrol       Date:  2004-03-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.